AIM To establish minimum clinically important difference(MCID) for measurements in an orthopaedic patient population with joint disorders.METHODS Adult patients aged 18 years and older seeking care for joint condition...AIM To establish minimum clinically important difference(MCID) for measurements in an orthopaedic patient population with joint disorders.METHODS Adult patients aged 18 years and older seeking care for joint conditions at an orthopaedic clinic took the Patient-Reported Outcomes Measurement Information System Physical Function(PROMIS~? PF) computerized adaptive test(CAT), hip disability and osteoarthritis outcome score for joint reconstruction(HOOS JR), and the knee injury and osteoarthritis outcome score for joint reconstruction(KOOS JR) from February 2014 to April 2017. MCIDs were calculated using anchorbased and distribution-based methods. Patient reports of meaningful change in function since their first clinic encounter were used as an anchor.RESULTS There were 2226 patients who participated with a mean age of 61.16(SD = 12.84) years, 41.6% male, and 89.7% Caucasian. Mean change ranged from 7.29 to 8.41 for the PROMIS~? PF CAT, from 14.81 to 19.68 for the HOOS JR, and from 14.51 to 18.85 for the KOOS JR. ROC cut-offs ranged from 1.97-8.18 for the PF CAT, 6.33-43.36 for the HOOS JR, and 2.21-8.16 for the KOOS JR. Distribution-based methods estimated MCID values ranging from 2.45 to 21.55 for the PROMIS~? PF CAT; from 3.90 to 43.61 for the HOOS JR, and from 3.98 to 40.67 for the KOOS JR. The median MCID value in the range was similar to the mean change score for each measure and was 7.9 for the PF CAT, 18.0 for the HOOS JR, and 15.1 for the KOOS JR.CONCLUSION This is the first comprehensive study providing a wide range of MCIDs for the PROMIS? PF, HOOS JR, and KOOS JR in orthopaedic patients with joint ailments.展开更多
目的观察火龙罐治疗早中期膝骨关节炎的临床疗效。方法将108例早中期膝骨关节炎患者随机分为对照组和观察组,每组54例。对照组给予塞来昔布胶囊治疗,观察组在对照组基础上给予火龙罐治疗。比较两组治疗前、治疗后、治疗后3个月疼痛视觉...目的观察火龙罐治疗早中期膝骨关节炎的临床疗效。方法将108例早中期膝骨关节炎患者随机分为对照组和观察组,每组54例。对照组给予塞来昔布胶囊治疗,观察组在对照组基础上给予火龙罐治疗。比较两组治疗前、治疗后、治疗后3个月疼痛视觉模拟量表(visual analog scale,VAS)评分、西安大略和麦克马斯特大学骨关节炎指数(Western Ontario and McMaster University osteoarthritis index,WOMAC)评分、Lysholm膝关节评分量表评分、血清炎症因子[白细胞介素-1β(interlenkin-1β,IL-1β)、白细胞介素-6(interlenkin-6,IL-6)、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)]水平以及膝关节伸肌和屈肌峰力矩。结果两组治疗后及治疗后3个月VAS评分较治疗前显著降低,且观察组VAS评分明显低于对照组,差异具有统计学意义(P<0.05)。两组治疗后及治疗后3个月WOMAC评分较治疗前显著降低,Lysholm膝关节评分量表评分较治疗前显著升高,且观察组WOMAC评分和Lysholm膝关节评分量表评分明显优于对照组,差异具有统计学意义(P<0.05)。两组治疗后及治疗后3个月血清IL-1β、IL-6和TNF-α水平较治疗前显著降低,且观察组血清IL-1β、IL-6和TNF-α水平明显低于对照组,差异具有统计学意义(P<0.05)。两组治疗后及治疗后3个月伸肌和屈肌峰力矩较治疗前显著升高,且观察组伸肌和屈肌峰力矩明显高于对照组,差异具有统计学意义(P<0.05)。结论火龙罐治疗早中期膝骨关节炎,可减轻炎症反应,增强膝关节周围肌肌力,缓解患者疼痛,改善膝关节功能。展开更多
基金National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health,No.U01AR067138.
文摘AIM To establish minimum clinically important difference(MCID) for measurements in an orthopaedic patient population with joint disorders.METHODS Adult patients aged 18 years and older seeking care for joint conditions at an orthopaedic clinic took the Patient-Reported Outcomes Measurement Information System Physical Function(PROMIS~? PF) computerized adaptive test(CAT), hip disability and osteoarthritis outcome score for joint reconstruction(HOOS JR), and the knee injury and osteoarthritis outcome score for joint reconstruction(KOOS JR) from February 2014 to April 2017. MCIDs were calculated using anchorbased and distribution-based methods. Patient reports of meaningful change in function since their first clinic encounter were used as an anchor.RESULTS There were 2226 patients who participated with a mean age of 61.16(SD = 12.84) years, 41.6% male, and 89.7% Caucasian. Mean change ranged from 7.29 to 8.41 for the PROMIS~? PF CAT, from 14.81 to 19.68 for the HOOS JR, and from 14.51 to 18.85 for the KOOS JR. ROC cut-offs ranged from 1.97-8.18 for the PF CAT, 6.33-43.36 for the HOOS JR, and 2.21-8.16 for the KOOS JR. Distribution-based methods estimated MCID values ranging from 2.45 to 21.55 for the PROMIS~? PF CAT; from 3.90 to 43.61 for the HOOS JR, and from 3.98 to 40.67 for the KOOS JR. The median MCID value in the range was similar to the mean change score for each measure and was 7.9 for the PF CAT, 18.0 for the HOOS JR, and 15.1 for the KOOS JR.CONCLUSION This is the first comprehensive study providing a wide range of MCIDs for the PROMIS? PF, HOOS JR, and KOOS JR in orthopaedic patients with joint ailments.
文摘目的观察火龙罐治疗早中期膝骨关节炎的临床疗效。方法将108例早中期膝骨关节炎患者随机分为对照组和观察组,每组54例。对照组给予塞来昔布胶囊治疗,观察组在对照组基础上给予火龙罐治疗。比较两组治疗前、治疗后、治疗后3个月疼痛视觉模拟量表(visual analog scale,VAS)评分、西安大略和麦克马斯特大学骨关节炎指数(Western Ontario and McMaster University osteoarthritis index,WOMAC)评分、Lysholm膝关节评分量表评分、血清炎症因子[白细胞介素-1β(interlenkin-1β,IL-1β)、白细胞介素-6(interlenkin-6,IL-6)、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)]水平以及膝关节伸肌和屈肌峰力矩。结果两组治疗后及治疗后3个月VAS评分较治疗前显著降低,且观察组VAS评分明显低于对照组,差异具有统计学意义(P<0.05)。两组治疗后及治疗后3个月WOMAC评分较治疗前显著降低,Lysholm膝关节评分量表评分较治疗前显著升高,且观察组WOMAC评分和Lysholm膝关节评分量表评分明显优于对照组,差异具有统计学意义(P<0.05)。两组治疗后及治疗后3个月血清IL-1β、IL-6和TNF-α水平较治疗前显著降低,且观察组血清IL-1β、IL-6和TNF-α水平明显低于对照组,差异具有统计学意义(P<0.05)。两组治疗后及治疗后3个月伸肌和屈肌峰力矩较治疗前显著升高,且观察组伸肌和屈肌峰力矩明显高于对照组,差异具有统计学意义(P<0.05)。结论火龙罐治疗早中期膝骨关节炎,可减轻炎症反应,增强膝关节周围肌肌力,缓解患者疼痛,改善膝关节功能。
